tirzepatide surpass cvot Comparison of and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular

While emerging research suggests genetic variations might influence medication response, routine genetic testing is not currently recommended in clinical practice

Treatment with RYBELSUS 14 mg once daily for 26 weeks resulted in non-inferior reductions in HbA1c compared to liraglutide 1.8 mg (see Table 7)

GERD occurs when acid reflux happens repeatedly over time, the Mayo Clinic says

PlexusDx patients can ask their healthcare provider which specific probiotic brands have the strongest evidence base for supporting GLP-1 therapy adaptation

It ensures that our cells function properly, which is essential for maintaining health and preventing disease

GLP-1 drugs are indicated for patients with obesity, i.e